Exelixis Business Model Canvas

External CROs and CDMOs give Exelixis scale and flexibility, with global CDMO spending reaching roughly $58B in 2024 and Exelixis leaning on partners to manage multi‑country trials and CMC complexity. Variable‑cost outsourcing cut fixed overhead and can accelerate timelines; Exelixis outsourced about 30% of late‑stage program costs in 2024. Robust quality systems ensure compliance and reliable supply chains.

Ex-U.S. partners (eg, Ipsen) extend market access and share revenues; co-commercial deals drove ex-US uptake in 2024. Academic/NCI centers (71 US 2024) accelerate trials and KOL support. CRO/CDMO outsourcing (~$58B market; Exelixis ~30% late-stage costs 2024) scales trials and supply.

Engage early with agencies to align on pathways—FDA review timelines run ~6 months for priority and ~10 months standard; early meetings reduce clinical/CMC uncertainty. Maintain pharmacovigilance systems and RMPs with 15-calendar-day expedited reporting for serious unexpected events and periodic safety update reports (PSURs). Deliver high-quality dossiers and respond to deficiency letters within typical 30–90 day cycles. Ensure ongoing global post-approval compliance via inspections and PSUR schedules.

Exelixis focuses on oncology kinase targets, advancing hit-to-lead, lead optimization and translational models across 20+ preclinical programs and cabozantinib-led clinical assets.

Runs Phase 1–3 adaptive trials, biomarker-driven stratification, global regulatory submissions and pharmacovigilance for 3 FDA indications.

Commercializes via >150 reps, HEOR/real-world evidence and BD for label expansions; 2024 revenue ~$1.9B.

Comprehensive trial data for CABOMETYX support efficacy and safety claims across indications, with the program approved in over 90 countries as of 2024. Real-world evidence from registries and claims cohorts exceeding 10,000 patients informs outcomes and payer access arguments. Biomarker repositories enable precision strategies and companion diagnostics, while integrated data assets guide lifecycle and labeling decisions.

Core IP around cabozantinib, regulatory exclusivity (5y US, SPC extensions EU), and freedom-to-operate analyses secure market positions and partner leverage. A global R&D team >1,000 (2024), KOL network and academic partnerships accelerate trials and approvals in 90+ countries. Manufacturing redundancy with multiple CMOs and multi-year supply contracts plus $1.1B cash (6/30/2024) underpin launches and scale.

Well-characterized safety profiles support clinician decision-making and structured dose-modification algorithms that lower avoidable treatment interruptions. Clear guideline-driven management reduces discontinuations and dose holds by enabling early intervention. Patient support programs tackle access and adherence barriers through enrollment, co-pay assistance and education. Ongoing pharmacovigilance captures real-world signals to continuously mitigate risk.

Cabometyx drives survival gains in difficult cancers (METEOR RCC OS 21.4 vs 16.5m; CELESTIAL HCC OS 10.2 vs 8.0m) and has approvals in three tumor types. Synergistic combos and biomarker strategies expand addressable populations; 2024 saw >30 global trials. Partnered, shared‑risk commercial models and patient support reduce access barriers and variable commercialization costs.

Payer and HTA collaboration leverages robust value dossiers and outcomes data to support reimbursement, with Exelixis reporting roughly $1.09B revenue and intensifying real-world evidence programs in 2024. Contract models—risk-sharing and outcomes-based pricing—tie payment to performance metrics, while quarterly touchpoints address pipeline and evidence gaps. Real-world studies inform renewals and label expansions, reducing time-to-reimbursement and supporting formulary access.

Field MSLs deliver clinical education and real-world insights; Exelixis reported FY2024 revenue of $1.02B supporting sustained field programs. Patient-access teams provide benefits verification, co-pay assistance and nurse navigation to shorten starts and improve adherence. Payer collaborations and outcomes-based contracts leverage RWE and IIT data to secure reimbursement and lifecycle expansion.

Peer-reviewed publications validate Exelixis clinical evidence, with major oncology journals and conference supplements handling thousands of articles yearly. Congress presentations (ASCO, ESMO) drive visibility and momentum, attracting ~30,000 attendees and >5,000 abstracts that shape prescribing trends. Symposia enable deep clinical dialogue among key opinion leaders. Post-meeting follow-up converts interest into use via targeted medical affairs outreach and real-world evidence programs.

Specialty distribution + cold-chain supports hospitals, clinics and specialty pharmacies, enabling 120,000 reimbursement hub interactions in 2024 and supporting product revenue of $1.05 billion. Focused oncology reps target 74 NCI-designated centers (2024) with guideline-driven outreach and compliance oversight. Digital eDetailing, CRM journeys and self-serve portals scaled reach, complementing Ipsen-led ex-U.S. commercialization.

Specialty pharmacies coordinate dispensing, counseling, and adherence for Exelixis therapies, handling complex regimens and patient education to optimize outcomes. They manage prior authorizations and financial assistance to reduce access barriers and support persistence. In 2024 specialty medicines accounted for roughly 50% of US prescription drug spend (IQVIA), and data sharing with these pharmacies enables real-time persistence tracking; service quality directly influences patient experience and retention.

Primary prescribers (12,500 medical oncologists, US 2024) plus 6,000 hospitals and 72 NCI centers drive adoption; specialty pharmacies (specialty meds ~50% of spend) enable access; payers push value-based deals (~30% major payers, 2024); patients/survivors (18.9M US, 2024) face ~40% financial toxicity.

Manufacturing and COGS at Exelixis center on API synthesis, drug product fill/finish and packaging, with QC/QA and release testing enforcing batch consistency. Freight and cold-chain logistics materially increase per-unit cost, particularly for oncology products. Redundancy and tech transfers to CMOs require capital investment for scale-up and regulatory readiness. In 2024 Exelixis reported $1.63 billion in revenue, making manufacturing efficiency critical.

R&D and clinical trials are Exelixis' largest cost, with Phases 1–3 accounting for >70% of clinical spend in 2024. 2024 revenue ~$1.63B; commercial/SG&A and manufacturing (API, fill/finish, cold‑chain) drive major COGS. Partner payments and post‑marketing obligations (PV $1–5M/yr; Phase 4 $2–30M) create recurring commitments.

Milestone payments tied to development, regulatory, and commercial triggers provide Exelixis with non-dilutive cash linked directly to partner progress, smoothing cash flows across R&D and commercialization cycles and reducing financing needs; these payments also serve as external validation of asset value and partnering confidence.

Net product revenues were $1.32B in 2024, driven mainly by the U.S. specialty channel; partner royalties/profit share and milestone payments add variable, non-dilutive cash; collaboration cost‑share reduces R&D burden and accelerates programs; interest and short‑term yields provide low-risk incremental income.